论文部分内容阅读
目的探讨对晚期上皮性卵巢癌患者进行新辅助化疗的临床应用效果。方法选取2014年6月~2015年6月我院收治的晚期上皮性卵巢癌患者42例作为研究对象,按照具体给予的治疗决策的不同分为探索组与可比组,各21例,探索组均于行传统切除术前和术后应用新辅助化疗措施,而可比组仅行传统切除术。对比评价两组患者于治疗后具体获得的疗效及血清CA125水平,并且追踪观察其治疗后1年内的实际存活率情况。结果探索组患者的总疗效率为80.95%(17/21)优于可比组的52.38%(11/21),探索组患者的血清CA125水平均值为(158.23±31.07)U/mL低于可比组的(292.35±50.81)U/mL,治疗后1年内探索组的实际存活率为90.48%(19/21)高于可比组76.19%(16/21),差异有统计学意义(P<0.05)。结论新辅助化疗手段能够帮助晚期上皮性卵巢癌患者显著改善疗效,其能够促进控制术后癌细胞的扩散进展,可获得相对理想的预后效果,对其近期生存的可能性可以起到一定的保障作用。
Objective To investigate the clinical effect of neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer. Methods Forty-two patients with advanced epithelial ovarian cancer who were treated in our hospital from June 2014 to June 2015 were selected as study subjects and divided into exploration group and comparable group according to the specific treatment decisions, 21 cases in each group Neoadjuvant chemotherapy was applied before and after conventional resection, whereas traditional resection was performed in comparable group. The curative effect and serum CA125 level were compared between two groups after treatment, and the actual survival rate within 1 year after treatment was tracked. Results The total effective rate of the exploration group was 80.95% (17/21), which was higher than that of the comparable group (52.38%, 11/21). The serum CA125 level in the exploration group was (158.23 ± 31.07) U / mL lower than that in the comparable group (292.35 ± 50.81) U / mL. The actual survival rate of the exploration group within one year after treatment was 90.48% (19/21), which was significantly higher than 76.19% (16/21) of the comparable group (P <0.05) . Conclusion Neoadjuvant chemotherapy can significantly improve the efficacy of advanced epithelial ovarian cancer patients, which can promote the control of postoperative proliferation of cancer cells and obtain a relatively satisfactory prognosis, which may provide some protection to the possibility of survival in the near future effect.